Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Pulmonary fibrosis, a progressive and irreversible manifestation of interstitial lung disease, leads to severe respiratory dysfunction. Although current therapies can slow disease progression, they cannot eliminate pathogenic fibroblasts, thereby limiting clinical efficacy. Chimeric antigen receptor (CAR) T-cell therapy has shown success in hematologic malignancies and autoimmune diseases and is being explored for non-malignant disorders.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
